{"id":75953,"date":"2024-02-14T13:03:48","date_gmt":"2024-02-14T12:03:48","guid":{"rendered":"https:\/\/www.veeva.com\/eu\/?post_type=resources&#038;p=75953"},"modified":"2025-08-13T14:34:44","modified_gmt":"2025-08-13T12:34:44","slug":"boehringer-ingelheim-partners-with-veeva-to-advance-its-clinical-and-regulatory-operations-in-animal-health","status":"publish","type":"resources","link":"https:\/\/www.veeva.com\/eu\/resources\/boehringer-ingelheim-partners-with-veeva-to-advance-its-clinical-and-regulatory-operations-in-animal-health\/","title":{"rendered":"Boehringer Ingelheim Partners with Veeva to Advance its Clinical and Regulatory Operations in Animal Health"},"content":{"rendered":"<p align=\"center\"><i>Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM<br class=\"hidden-xs\"> for greater efficiency, visibility, and speed<\/i><\/p>\n<p><strong>BARCELONA, Spain \u2014 14 Feb. 2024 \u2014<\/strong> <a href=\"\/eu\/\">Veeva Systems<\/a> (NYSE: VEEV) today announced that Boehringer Ingelheim has selected <a href=\"\/eu\/products\/veeva-clinical-platform\/\">Veeva Vault Clinical<\/a> and <a href=\"\/eu\/products\/veeva-rim\/\">Veeva Vault RIM<\/a> applications as its technology foundation for clinical and regulatory management in its animal health business unit. By adopting unified applications on a single platform, Boehringer Ingelheim can streamline clinical execution to speed development of new medicines that help animals live healthier and happier lives.<\/p>\n<p>\u201cVeeva Vault Clinical and Veeva Vault RIM will help us drive higher operational efficiency across functions while providing the insights for data-driven decision making,\u201d said Marcus Gravendyck, head of global regulatory affairs and pharmacovigilance, Animal Health at Boehringer Ingelheim. \u201cThis will allow us to execute and innovate faster to improve the lives of animals.\u201d<\/p>\n<p>Boehringer Ingelheim will use <a href=\"\/eu\/products\/veeva-ctms\/\">Veeva Vault CTMS<\/a> in its animal health business unit to manage and monitor trials and <a href=\"\/eu\/products\/veeva-etmf\/\">Veeva Vault eTMF<\/a> for real-time inspection readiness, visibility, and control. The company will also use Vault RIM applications, including <a href=\"\/eu\/products\/veeva-registrations\/\">Veeva Vault Registrations<\/a>, <a href=\"\/eu\/products\/veeva-submissions\/\">Veeva Vault Submissions<\/a>, and <a href=\"\/eu\/products\/veeva-submissions-archive\/\">Veeva Vault Submissions Archive<\/a> for advanced regulatory processes. Connecting these applications on a single cloud platform will enable real-time access to data and seamless information exchange.<\/p>\n<p>\u201cBoehringer Ingelheim is driving innovation to accelerate the development of new treatments for animals,\u201d said Thomas Reith, corporate vice president, IT research, development, and medicine at Boehringer Ingelheim. \u201cBy establishing a centralized and digital foundation with Veeva, we can deliver a better user experience for our teams, and offer lean, end-to-end processes for speed and agility.\u201d<\/p>\n<p>\u201cWe\u2019re proud to partner with Boehringer Ingelheim in animal health to simplify their clinical development and regulatory processes,\u201d said Stefan Jahnecke, vice president of animal health strategy at Veeva. \u201cVeeva Vault Clinical and Veeva Vault RIM will help Boehringer Ingelheim increase data integrity and provide the visibility to quickly adapt to changing business requirements.\u201d<\/p>\n<p>Vault Clinical and Vault RIM are part of <a href=\"\/eu\/products\/development-cloud\/\">Veeva Development Cloud<\/a>, the technology foundation for product development across clinical, regulatory, quality, and safety. To learn more, visit <a href=\"\/eu\/products\/development-cloud\/\">veeva.com\/eu\/DevelopmentCloud<\/a>.<\/p>\n<p><strong>About Veeva Systems<\/strong><br \/>\nVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world\u2019s largest biopharmaceutical companies to emerging biotechs. As a <a href=\"\/pbc\/\" rel=\"noopener noreferrer\" target=\"_blank\">Public Benefit Corporation<\/a>, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit <a href=\"\/eu\/\">veeva.com\/eu<\/a>.<\/p>\n<p><strong>Veeva Forward-looking Statements<\/strong><br \/>\nThis release contains forward-looking statements regarding Veeva\u2019s products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended October 31, 2023, which you can find <a href=\"https:\/\/www.sec.gov\/ixviewer\/ix.html?doc=\/Archives\/edgar\/data\/0001393052\/000139305223000066\/veev-20231031.htm#if2b44b52628b48dba41a9b157f45bcfe_124\" rel=\"noopener noreferrer\" target=\"_blank\">here<\/a> (a summary of risks which may impact our business can be found on pages 38 and 39), and in our subsequent SEC filings, which you can access at <a href=\"https:\/\/www.sec.gov\/\" rel=\"noopener noreferrer\" target=\"_blank\">sec.gov<\/a>.<\/p>\n<p class=\"text-center\">###<\/p>\n<p>\n<strong>Contact:<\/strong><br \/>\nJeremy Whittaker<br \/>\nVeeva Systems<br \/>\n+49-695-095-5486<br \/>\n<a href=\"mailto:jeremy.whittaker@veeva.com\">jeremy.whittaker@veeva.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Global animal health leader adopts Veeva Vault Clinical and Veeva Vault RIM for greater efficiency, visibility, and speed.<\/p>\n","protected":false},"featured_media":75992,"parent":0,"template":"","class_list":["post-75953","resources","type-resources","status-publish","has-post-thumbnail","hentry","resource-html-content-yes","resource-area-20-clinical-operations","resource-area-20-regulatory","resource-product-20-ctms","resource-product-20-etmf","resource-product-20-registrations","resource-product-20-submissions","resource-product-20-submissions-archive","resource-type-news-press-release","resource-type-press-release"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/75953"}],"collection":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources"}],"about":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/types\/resources"}],"version-history":[{"count":1,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/75953\/revisions"}],"predecessor-version":[{"id":75991,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/resources\/75953\/revisions\/75991"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media\/75992"}],"wp:attachment":[{"href":"https:\/\/www.veeva.com\/eu\/wp-json\/wp\/v2\/media?parent=75953"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}